SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to fresh 52-week highs ahead of the Q3 report is drawing attention, with traders focused on BRIUMVIs sales growth and possible guidance updates. Buyout and short-squeeze theories are circulating but remain speculation; the upcoming subcutaneous BRIUMVI data is another anticipated catalyst, while some traders warn the rally may already reflect high expectations.

Lennar Corp. engages in the provision of real estate related financial and investment management services. It operates through the following segments: Homebuilding, Financial Services, Multifamily, and Lennar Other. The Homebuilding segment refers to the construction and sale of single-family attached and detached homes and the purchase, development, and sale of residential land directly and through entities. The Financial Services segment focuses on mortgage financing, title, and closing services for buyers. The Multifamily segment is involved in the development, construction, and property management of multifamily rental properties. The Lennar Other segment includes funds, asset management platform, and strategic investments in technology companies. The company was founded in 1954 and is headquartered in Miami, FL.

Lennar Corp. - Ordinary Shares - Class A

Lennar Corp.

Berkshires disclosed accumulation of a large Lennar stake has fueled bargain-buying interest, but traders are debating it against Hunterbrooks short-report allegations about Lennars transactions with spinoff Millrose. The dispute adds to concerns over weak results and outlook, pressured affordability, and elevated mortgage rates.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is drawing attention after traders cited a Northland upgrade tied to its C3 Code agentic-AI platform, alongside heavy call activity and the stocks potential as a short-squeeze candidate. Bullish traders see a turnaround opportunity, while skeptics point to declining revenue and persistent losses as reasons for caution.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. The firm offers annealing and gate-model quantum computing technologies. It provides professional services that assist customers in identifying and implementing quantum computing applications and selling quantum computer systems to customers. The company was founded by Eric Ladizinsky in 1999 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave shares are drawing attention amid a steep selloff across quantum-computing stocks, with traders questioning whether high valuations, limited near-term commercialization and competition from classical AI can support the sector ahead of Q3 results. Some see the pullback as a buying opportunity, while others expect more downside.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons stronger-than-expected third-quarter results, led by Dupixent and Eylea HD, drove a sharp share-price jump and a fresh high. Traders largely welcomed the report, while debating whether the breakout can hold and pointing to heavy call-option activity.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

Discussion centers on REalloys speculative role in a North American rare-earth and magnet supply chain ahead of 2027 U.S. defense sourcing restrictions, including its Army-linked Tooele opportunity and Tanbreez offtake agreement. Bulls point to strategic demand and potential sector momentum, while skeptics cite limited company updates, execution risk and sharp volatility; the Tooele discussions are not presented as a finalized agreement.

KLA Corp. engages in the supply of process control and yield management solutions for the semiconductor and related nano-electronics industries. The company operates through the following segments: Semiconductor Process Control, Specialty Semiconductor Process, and PCB, Display and Component Inspection. The Semiconductor Process Control segment provides a comprehensive portfolio of inspection, metrology and data analytics products and related services. The Specialty Semiconductor Process segment develops and sells advanced vacuum deposition and etching process tools. The PCB, Display and Component Inspection segment enables electronic device manufacturers to inspect, test and measure PCBs, flat panel displays and ICs to verify their quality. Its products include manufactured chips, reticle, packaging, surface profilers, nanochemical testers, KT pro equipment, and compound semiconductors. The company was founded on July 9, 1975 and is headquartered in Milpitas, CA.

KLA Corp.

KLAs quarterly results topped expectations and its forward outlook was strong, but shares have sold off amid broader semiconductor weakness and analyst price-target cuts. Traders are divided between viewing the decline as an overreaction and buying opportunity, and worrying that the stocks downtrend and valuation pressure may persist.

Backblaze, Inc. operates as a cloud provider for businesses and consumers to store, use, and protect their data. The firm provides a foundation for businesses, developers, IT professionals, and individuals to store, backup, and archive data, host content, manage media, and build their applications. It also offers B2 Cloud Storage and Computer Backup services. The company was founded by Timothy Nufire, Gleb Budman, Charles Jones, Kwok Hang Ng, Brian Wilson, Nilay Patel and Damon Uyeda in 2007 and is headquartered in San Francisco, CA.

Backblaze Inc - Ordinary Shares - Class A

BLZE is under pressure after a steep pullback, with traders pointing to broader tech weakness and CoreWeaves decline while positioning around the upcoming earnings report. The community is split between dip-buyers betting on strong results or new contracts and cautious traders concerned that earnings could bring further losses.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is falling amid a broad semiconductor selloff that traders attribute largely to Intels weak forward guidance, with some also pointing to bearish put-option activity. The community is split between buying the pullback and expecting further downside, while noting the drop appears tied more to sector pressure than a clear Qualcomm-specific catalyst.

BitGo Holdings, Inc. operates as a digital asset infrastructure company delivering custody, wallets, staking, trading, financing, stablecoins, and settlement services from regulated cold storage. It focuses on accelerating the transition of the financial system to a digital asset economy. The company was founded by Michael Belshe and Ben Davenport in 2013 and is headquartered in Sioux Falls, SD.

BitGo Holdings Inc. - Ordinary Shares - Class A

BitGos latest earnings are drawing attention: traders are weighing strong revenue growth against a wider net loss, with some blaming the results for renewed share-price weakness. Bullish investors argue that Bitcoins recovery and expanding custody and institutional services could support a rebound, while others remain concerned about profitability and the stocks persistent decline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers

Pharvaris (NASDAQ:PHVS) stock moved upwards by 19.4% to $36.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.0 billion.
CalciMedica (NASDAQ:CALC) shares roseread more...

CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints

CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential...

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers

Autonomix Medical (NASDAQ:AMIX) stock rose 49.1% to $4.1 during Tuesday's after-market session. The market value of their outstanding shares is at $1.5 million.
CalciMedica (NASDAQ:CALC) shares rose 9.8%read more...

CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program

CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program PR Newswire LA JOLLA, Calif., June 24, 2026...

CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data

CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data PR Newswire LA JOLLA, Calif., June 24, 2026 FDA...

CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates...

CalciMedica Reports 2025 Financial Results and Provides Clinical Updates

CalciMedica Reports 2025 Financial Results and Provides Clinical Updates CalciMedica Reports 2025 Financial Results and Provides Clinical Updates PR Newswire LA JOLLA, Calif., March 3, 2026 Internal...

How Is The Market Feeling About CalciMedica Inc?

CALC Stock Slumped 76% On Wednesday — Here’s Why

Equity

CalciMedica said that it has decided to discontinue the trial evaluating its lead product candidate Auxora in patients with Stage 2 or Stage 3 acute kidney injury following a committee recommendation. 


CalciMedica (NASDAQ:CALC) Upgraded to Sell at Wall Street Zen

Wall Street Zen upgraded CalciMedica to a "sell" rating in a report on Saturday...

CalciMedica, Inc. is a clinical-stage biopharmaceutical company, which engages in developing therapies for life-threatening inflammatory diseases. The firm's product candidate, Auxora, helps in treating acute pancreatitis and asparaginase-associated pancreatitis. The company was founded by Kenneth A. Stauderman and Gonul Velicelebi in 2007 and is headquartered in La Jolla, CA.

CalciMedica Inc

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>According to the company, the committee said that the safety concerns warrant reevaluation of the study design, particularly with respect to patient enrollment criteria. &nbsp;</li><li>There were no deaths in the trial related to the study drug or any serious adverse events that warranted expedited reporting to the U.S. Food and Drug Administration, the company added.</li><li>Oppenheimer sees the stock as oversold on today's news and "significantly undervalued."</li></ul>CalciMedica (CALC) shares closed down 76% and edged further 4% lower after-hours on Wednesday after the company said that it has decided to discontinue the trial evaluating its lead product candidate Auxora in patients with Stage 2 or Stage 3 acute kidney injury with associated acute hypoxemic respiratory failure.<h2 class="st-heading-2">Rationale For Discontinuation</h2>The biopharmaceutical company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/calcimedica-announces-discontinuation-of-phase-2-kourage-trial-in-aki-following-independent-data-monitoring-committee-recommendation-302671925.html">said</a> that the discontinuation decision followed a recommendation from an independent data monitoring committee that identified a safety concern.According to the company, the committee said that the safety concerns warrant reevaluation of the study design, particularly with respect to patient enrollment criteria. &nbsp;There were no deaths in the trial related to the study drug or any serious adverse events that warranted expedited reporting to the U.S. Food and Drug Administration, the company added.CalciMedica will now perform a review of the clinical data, which will inform how evaluation of Auxora will proceed in acute kidney injuries. &nbsp;"Based on the IDMC's feedback, we will review the unblinded KOURAGE data and explore modifications to the trial design, particularly patient enrollment criteria, that may support further clinical testing of Auxora in patients with AKI," said CEO Rachel Leheny.CalciMedica is also evaluating Auxora in acute pancreatitis and severe COVID-19 pneumonia.<h2 class="st-heading-2">Analyst Take</h2>Oppenheimer on Wednesday said that shares of CALC were oversold after the company announced the discontinuation of the mid-stage trial in patients with kidney injury.Oppenheimer said that it caught up with management following the news, who said the safety concern identified by the independent committee's review of unblinded data "appears to stem not from the drug itself, but from aspects of this particular trial."The firm sees the stock as oversold on today's news and "significantly undervalued." Even if one removes any revenue potential in AKI from projections, Auxora's derisked $200M opportunity in acute pancreatitis alone supports a favorable outlook, the analyst said.The firm has an ‘Outperform’ rating on CalciMedica shares.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CALC stock jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.A Stocktwits user voiced hopes for a rebound in share price to sell.<stembedurl>https://www.stocktwits.com/tragusa/message/643195813</stembedurl>Another echoed Oppenheimer and said that the stock is oversold for the news. “This should correct itself either fast or slow but it will correct itself,” they said.<stembedurl>https://www.stocktwits.com/Lay1a/message/643185864</stembedurl><a href="https://stocktwits.com/symbol/CALC">CALC stock</a> has dropped 53% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-q4-2025-earnings/cmyg0wMR40q">Tesla Shares Rise After Hours As EV Giant Commits To Vehicle Autonomy, AI With Cybercab And $2B xAI Investment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

CalciMedica said that it has decided to discontinue the trial evaluating its lead product candidate Auxora in patients with Stage 2 or Stage 3 acute kidney injury following a committee recommendation. 

Vanguard Total Stock Market ETF

Vanguard Extended Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$1.46
Prev Close	$1.75
Open	$1.79
Dividend Yield	0.00%
50-Day Moving Average	$1.76
Beta	0.33
Avg. Volume	79,260.33
PE Ratio	-0.22

52-Week High	$36.00
52-Week Low	$1.00
Market Capitalization	$9.97M
EPS (Annual)	-$9.85
Price to Book	1.63
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

CALC Fundamentals